Literature DB >> 9917077

Human immunodeficiency virus protease inhibitors.

K Z Rana1, M N Dudley.   

Abstract

Human immunodeficiency virus (HIV) protease inhibitors have revolutionized the treatment of individuals infected with this pathogen. The protease is an enzyme that is essential for viral replication because it cleaves both structural and functional proteins from precursor viral polyprotein strands. Inhibition of this process suppresses viral replication, which produces immature noninfectious virions. When combined with reverse transcriptase inhibitors, these agents are very potent in suppressing viral replication. Pharmacologic properties, toxic profile, drug interactions, and resistance patterns differ among protease inhibitors, and all must be considered when selecting the drugs for therapeutic use in humans. The best combination, sequence of use, durability of response, and magnitude of immune reconstitution and function are issues that have yet to be fully elucidated.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9917077     DOI: 10.1592/phco.19.1.35.30513

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  14 in total

1.  Inhibition of the HIV-1 and HIV-2 proteases by a monoclonal antibody.

Authors:  J Lescar; J Brynda; P Rezacova; R Stouracova; M M Riottot; V Chitarra; M Fabry; M Horejsi; J Sedlacek; G A Bentley
Journal:  Protein Sci       Date:  1999-12       Impact factor: 6.725

2.  Drug Interactions with Antiretrovirals.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-06       Impact factor: 3.725

3.  Pharmacokinetic modeling and simulations of interaction of amprenavir and ritonavir.

Authors:  Mark Sale; Brian M Sadler; Daniel S Stein
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

4.  GF120918, a P-glycoprotein modulator, increases the concentration of unbound amprenavir in the central nervous system in rats.

Authors:  Jeffrey E Edwards; Kenneth R Brouwer; Patrick J McNamara
Journal:  Antimicrob Agents Chemother       Date:  2002-07       Impact factor: 5.191

5.  Lopinavir.

Authors:  M Hurst; D Faulds
Journal:  Drugs       Date:  2000-12       Impact factor: 9.546

Review 6.  Delavirdine: a review of its use in HIV infection.

Authors:  L J Scott; C M Perry
Journal:  Drugs       Date:  2000-12       Impact factor: 9.546

7.  HEPT derivatives as non-nucleoside inhibitors of HIV-1 reverse transcriptase: QSAR studies agree with the crystal structures.

Authors:  Anderson Coser Gaudio; Carlos Alberto Montanari
Journal:  J Comput Aided Mol Des       Date:  2002-04       Impact factor: 3.686

Review 8.  Nelfinavir: an update on its use in HIV infection.

Authors:  A Bardsley-Elliot; G L Plosker
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

9.  Effects of the human immunodeficiency virus-protease inhibitor, ritonavir, on basal and catecholamine-stimulated lipolysis.

Authors:  Diane C Adler-Wailes; Hanguan Liu; Faiyaz Ahmad; Ningping Feng; Constantine Londos; Vincent Manganiello; Jack A Yanovski
Journal:  J Clin Endocrinol Metab       Date:  2005-03-01       Impact factor: 5.958

10.  Lopinavir/ritonavir in the treatment of HIV-1 infection: a review.

Authors:  Ashish Chandwani; Jonathan Shuter
Journal:  Ther Clin Risk Manag       Date:  2008-10       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.